Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Drug Injury
  • About Our Firm
  • Free Case Evaluation
  • Frequently Asked Questions

Safety of Beovu Update: Study Results Announcement by Novartis and Beovu Label Change in Europe

September 24, 2020 By Law Offices of Thomas J. Lamb, P.A.

A September 2020 announcement by Novartis about recent Beovu study results had an emphasis on the safety of Beovu. However, this is understandable in view of a February 2020 notification issued by the American Society of Retina Specialists (ASRS) which raised questions about the safety of Beovu.

We get the following from this September 14, 2020, Fierce Pharma article, “Novartis, stressing Beovu safety, matches Eylea in head-to-head diabetic macular edema trial”, about that Novartis announcement about a Phase 3 Beovu study:

Normally, late-stage trial announcements center on a drug’s efficacy, but Novartis singled out Beovu’s safety performance in its statement. Beovu demonstrated a safety profile comparable to Eylea’s, including the rate of intraocular inflammation, the company noted….

The intraocular inflammation safety signal led to an update to Beovu’s U.S. and [European Union (EU)] labels, which now include information about retinal vasculitis and retinal vascular occlusion, which can cause blindness. To better understand the problem, Novartis has put together a panel of experts from both within and outside the company to examine its root cause, potential risk factors and mitigation measures.

For information concerning the September 2020 European Beovu label change, you may want to look at this Novartis press release: “European Medicines Agency (EMA) approves safety label update for Novartis Beovu®”.

As background, Novartis had been counting on Beovu to challenge market-leading Eylea, but the ASRS Beovu alert was a set-back for Novartis. The financial consequence of this concern about the safety of Beovu was explained in an August 2020 Reuters news report as follows: “[Novartis Chief Executive Vas Narasimhan said in an interview that he] believes safety problems that emerged with new eye medicine Beovu have cost Novartis shares 10% of their value.”

Of course, we will continue to watch for more new developments related to the safety of Beovu.

[View article at original source]

Beovu

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Unsafe Drugs Tagged With: Beovu, blindness, intraocular inflammation, retinal vascular occlusion, retinal vasculitis, vision loss

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Cases
  • Breast Implant Cases
  • Philips Breathing Devices Cases
  • GenX Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2022 · Law Offices of Thomas J. Lamb, P.A.